OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
49
Results
Show all
Save search
Copy query
Show results for
Unknown
(49)
Publication Date
Release Date
2018
(30)
2024
(4)
2020
(4)
2021
(3)
2025
(2)
2016
(2)
2023
(1)
2019
(1)
2017
(1)
2014
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression.
Not available
S-EPMC6026264
|
biostudies-literature
Cite
A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease.
Not available
S-EPMC4848212
|
biostudies-literature
Cite
Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus.
Not available
S-EPMC4216374
|
biostudies-literature
Cite
Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects.
Not available
S-EPMC5516277
|
biostudies-literature
Cite
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
Not available
S-EPMC6075717
|
biostudies-literature
Cite
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
Not available
S-EPMC5916814
|
biostudies-literature
Cite
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Not available
S-EPMC6075733
|
biostudies-literature
Cite
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Not available
S-EPMC6070353
|
biostudies-literature
Cite
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Not available
S-EPMC5961503
|
biostudies-literature
Cite
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Not available
S-EPMC6029450
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets